← Back to headlines
AstraZeneca Breast Cancer Drug Candidate Fails FDA Panel Vote
AstraZeneca's experimental breast-cancer drug candidate did not receive a favorable vote from an FDA panel, impacting its path to potential approval.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
